In particular, dishevelled binding antagonist of beta catenin 2 (DACT2) that binds to β-catenin preventing its transactivator activity presents, in many CRC, a hypermethylated promoter that correlates with lower expression in tumor tissue compared with normal tissue. This evidence concerns the gene DACT2 and colorectal carcinoma.